Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: Applied Immune Sciences

This article was originally published in The Gray Sheet

Executive Summary

Applied Immune Sciences: Receives $21.5 mil. in cash from the sale of newly issued common stock to Rhone-Poulenc Rorer. The sale was made in conjunction with AIS' meeting the second of three funding milestones under a 1993 strategic alliance between the two companies ("The Gray Sheet" June 7, 1993, p. 10). AIS reached the milestone by gaining FDA approval for a clinical trial investigating "a new approach to adjunctive leukemia therapy that is based on research indicating that infused T cell depleted donor peripheral blood improves the immune response of the leukemia patient after allogeneic bone marrow transplantation." AIS received a $21 mil. investment from RPR in January following approval of an investigational device exemption for the AIS CELLector device for purging T and B cells from allogeneic bone marrow ("The Gray Sheet" Jan. 23, 1995). The CELLector will be used in the newly approved trial as well...

You may also be interested in...



Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain

Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.

UsernamePublicRestriction

Register

MT004048

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel